



Universiteit  
Leiden  
The Netherlands

## The bone and cartilage interplay in osteoarthritis: key to effective treatment strategy

Tuerlings, M.

### Citation


Tuerlings, M. (2023, September 27). *The bone and cartilage interplay in osteoarthritis: key to effective treatment strategy*. Retrieved from <https://hdl.handle.net/1887/3642518>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3642518>

**Note:** To cite this publication please use the final published version (if applicable).



# **CHAPTER 1**




## **General introduction**



## Burden of Osteoarthritis

Osteoarthritis (OA) is a prevalent degenerative, yet irreversible, disease of the articular joints. Globally, 7% percent of the population is affected by OA and in 2019 OA was the 15<sup>th</sup> highest cause of years lived with disability (YLDs) [1]. Prevalence of OA increases significantly with increasing age and incidence rate is higher in women than in men, especially between 55 and 59 years of age [2]. OA pathophysiology is characterized by progressive and heterogeneous deterioration and loss of articular cartilage, remodeling of subchondral bone, osteophyte formation, and inflammation (**Figure 1**) [3]. Clinical symptoms of OA are pain, (morning) stiffness, crepitus, and reduced range of motion [4, 5]. Therefore, OA has a negative impact on patient quality of life and with progression of the disease it could even result in complete disability. So far, no disease modifying treatments are available, except for costly total joint replacement surgery at end-stage disease. This results in high social and economic burden to society [2, 6, 7]. OA pathophysiology is a complex process in which initiation and progression of the disease is mostly multifactorial [8]. Risk factors for OA include age, sex, metabolic health, aberrant loading, trauma, and genetics [9, 10].



**Figure 1 – Overview of osteoarthritis pathophysiology as age-related disease.**


(A) Schematic overview of OA pathophysiology including cartilage degeneration, subchondral bone remodeling, osteophyte formation, and inflammation (created with Biorender.com). (B) Overview of number of patients diagnosed with OA in the Netherlands in 2020 according to CBS, stratified by age.

## (Patho-)physiology of the osteochondral unit

Development and growth of longitudinal bones relies on a process called endochondral ossification (**Figure 2**). During prenatal development a cartilage template is formed, which is pre- and postnatally replaced by bone tissue. During endochondral ossification, chondrocytes present in the cartilage template become hypertrophic and start to secrete factors such as runt-related transcription factor 2 (*RUNX2*), vascular endothelial growth factor (*VEGF*), and collagen type 10 (*COL10*) [11]. Subsequently, the cartilage template is invaded by osteoblast progenitors, blood vessels, endothelial cells, and hematopoietic


cells that give rise to formation of osteoclasts, together resulting in resorption of hypertrophic cartilage and deposition of trabecular bone and bone marrow tissue in the so-called primary ossification center [12]. This primary ossification center expands and a secondary ossification center appears in the epiphysis of the developing bone, leaving the epiphyseal growth plate in between. The epiphyseal growth plate is responsible for the longitudinal growth of bones. With age this growth plate gets thinner, until both ossification centers fuse.

The cartilage at the end of bones escapes the endochondral ossification process, forming an avascular load-bearing structure called articular cartilage (**Figure 2**) [13, 14]. Chondrocytes are thought to be the only cell type present in articular cartilage and they reside in a maturational arrest state and do not proliferate. Chondrocytes are responsible for structural integrity of cartilage extracellular matrix (ECM), which consists of four zones: superficial, middle, deep, and calcified zone, with each zone having its specific fiber and cell organization (**Figure 3**) [13]. Main cartilage ECM components are collagens, such as collagen type 2 (*COL2*), and proteoglycans, such as aggrecan (*ACAN*). With OA, chondrocytes lose their maturational arrested state and become hypertrophic-like, resembling growth plate morphology. Thereby, they start to actively produce catabolic enzymes, such as matrix metalloproteinases (*MMPs*) and disintegrin and metalloproteinase with thrombospondin motifs 4 and 5 (*ADAMTS-4* and *-5*) [15-17]. These enzymes result in fragmentation and degradation of collagens and proteoglycans, respectively. Moreover, the reactivated chondrocytes secrete



**Figure 2 – Schematic overview of endochondral ossification process.**

A cartilage template is pre- and postnatally replaced by bone tissue. First, chondrocytes become hypertrophic and a primary ossification center is formed. This primary ossification center expands and a secondary ossification center develops in the epiphysis of the cartilage template, leaving the epiphyseal growth plate in between. With age this growth plate gets thinner, until both ossification centers fuse (created with Biorender.com).



**Figure 3 – Schematic overview of osteochondral structure.**

Cartilage consist of multiple zones, including the superficial, middle, deep, and calcified zone. The subchondral bone can be divided in the subchondral cortical plate and subchondral trabecular bone (created with Biorender.com).

factors promoting calcification and vascularization of the ECM, such as runt-related transcription factor 2 (RUNX2), vascular endothelial growth factor (VEGF), and collagen type X (COL10A1) [18, 19]. The degeneration and mineralization of cartilage in OA is accompanied with alterations in the subchondral bone.

The subchondral bone consists of subchondral cortical plate and subchondral trabecular bone. The subchondral cortical plate is defined as a thin cortical bone structure beneath the calcified cartilage, which is invaded with blood vessels and nerves. The subchondral trabecular bone is more porous, contains even more blood vessels and nerves compared to the cortical plate and is important in shock-absorbing [20]. Cell types residing in the subchondral bone are osteoblasts, osteocytes, and osteoclasts. Osteoblasts and osteocytes are responsible for production and maintenance of bone matrix, while osteoclasts are responsible for bone resorption in response to environmental factors, such as mechanical loading [21]. Main constituent of subchondral bone is collagen type 1 (COL1), which forms a network that serves as a scaffold for hydroxyapatite crystal deposition [22, 23]. In healthy bone, there is a balance between bone ECM production and resorption. However, with OA, this balance gets disturbed, resulting in increased subchondral bone plate thickness and decreased bone mineral density (BMD) in end-stage OA [22, 24, 25]. Together, increased subchondral bone plate thickness and mineralization of articular cartilage result in joint space narrowing, a typical characteristic of OA [5]. Another feature commonly seen in OA is the formation of bony

structures along the joint margins, called osteophytes. Osteophytes are formed through endochondral ossification in presence of growth factors transforming growth factor beta (TGF- $\beta$ ) and bone morphogenic protein 2 (BMP2) and they are hypothesized to increase joint stability in response to the enlarged mechanical load applied [26, 27].

### Genetics

Although development of OA is multifactorial, genetic predisposition is one of the strongest determinants of the disease [10]. To identify genetic variants and/or genes conferring risk to OA, comprehensive genome-wide association studies (GWASs) have been performed [28-33]. In GWASs genetic variants, called single nucleotide polymorphisms (SNPs), are being statistically associated to a specific disease or trait [34]. Since OA is a polygenic disease, with multiple causal genes showing small effects, effect sizes of OA susceptibility SNPs are generally low and large sample sizes are required to identify these SNPs [35]. The largest GWAS meta-analysis so far identifying OA risk SNPs is performed recently by Boer and colleagues [28]. This study included 826,690 individuals, of which 177,517 were diagnosed with OA and resulted in identification of 100 independent SNPs being associated with OA. These variants were located near genes including WW domain containing E3 ubiquitin protein ligase 2 (*WWP2*), interleukin 11 (*IL11*), transforming growth factor alpha (*TGF- $\alpha$* ), and aldehyde dehydrogenase 1 family member A2 (*ALDH1A2*) (**Table 1**). These genes are involved in maintenance processes in both bone and cartilage, confirming that both tissues have a substantial role in initiation and development of OA and stressing the importance of including both tissues and their interaction in OA research.

### Functional genomics

Next to identification of OA susceptibility genes, better understanding of molecular OA pathogenesis is required towards development of disease modifying treatments. A valuable tool for this is transcriptomic data, such as RNA-sequencing data, as it can be used to identify genes that mark OA pathophysiology, identify OA subtypes, and it can be used to determine the direction of effect of compelling OA risk genes.

#### *Differential expression analysis*

To identify underlying genes and pathways that mark OA pathophysiology, multiple studies have been performed comparing healthy or macroscopically preserved and lesioned OA areas of the joint on transcriptomic level [61-63]. In this respect, RNA-sequencing (RNA-seq) was performed on articular cartilage from patients who underwent total joint replacement surgery due to OA as part of the Research in Articular osteoArthritis Cartilage (RAAK) study. Upon comparing gene expression levels of macroscopically preserved and lesioned OA articular cartilage, 2387 genes

Table 1 – Notable examples of OA susceptibility SNPs, identified in genome wide association studies, with their mapped genes and hypothesized direction of effect.  
These genes are all involved in maintenance processes of both articular cartilage and subchondral bone.

| Mapped gene | Function of protein                                                            | SNP         | Risk allele | Trait           | Annotation    | Gene expression risk | References              |
|-------------|--------------------------------------------------------------------------------|-------------|-------------|-----------------|---------------|----------------------|-------------------------|
| IL11        | Regulates bone formation, remodeling, and resorption                           | rs4252548   | T           | Hip OA          | Missense      | Decreased expression | [28, 31, 32, 36]        |
| SMAD3       | Prevents chondrocyte hypertrophy                                               | rs12908498  | C           | Hip OA          | Intron        | Decreased expression | [28, 37-39]             |
| DIO2        | Induces chondrocyte hypertrophy                                                | rs225014    | T           | Symptomatic OA  | Exon          | Increased expression | [40, 41]                |
| TNC         | Promotes cartilage repair                                                      | rs1330349   | C           | Hip OA          | Intron        | Decreased expression | [28, 32, 42, 43]        |
| COL27A1     | Involved in transition from cartilage to bone                                  | rs72760655  | A           | Knee and hip OA | Upstream gene | Decreased expression | [28, 38, 44, 45]        |
| GDF5        | Involved in joint development and cartilage repair                             | rs143384    | A           | Knee OA         | 5' UTR        | Decreased expression | [28, 31, 32, 44, 46-48] |
| WWP2        | Plays a role in chondrogenesis                                                 | rs34195470  | A           | Knee OA         | Intron        | Increased expression | [28, 31, 38, 42, 49]    |
| MGP         | Regulates cartilage calcification                                              | rs1800801   | C           | Hand OA         | Exon          | Decreased expression | [50-52]                 |
| TGF-α       | Involved in transition from cartilage to bone                                  | rs3771501   | T           | Hip OA          | Intron        | Increased expression | [28, 32, 53, 54]        |
| ALDH1A2     | Involved in maintenance of cartilage and bone                                  | rs11071366  | A           | Hand OA         | Intron        | Decreased expression | [28, 55]                |
| CHADL       | Negative modulator of chondrocyte differentiation                              | rs117018441 | T           | Hip OA          | Intron        | Increased expression | [29, 31]                |
| COL11A1     | Involved in endochondral ossification and microarchitecture of developing bone | rs3753841   | T           | Hip OA          | Missense      | Decreased expression | [31, 56]                |
| FRZB        | Involved in endochondral ossification                                          | rs288326    | G           | Hip OA          | Exon          | Decreased expression | [57-60]                 |

were identified as being false discovery rate (FDR) significantly differentially expressed [63]. These differentially expressed genes were enriched for processes involved in extracellular matrix organization, characterized by upregulation of periostin (*POSTN*), TNF receptor superfamily member 11b (*TNFRSF11B*) and secreted phosphoprotein 1 (*SPP1*) and processes involved in skeletal system development, characterized by upregulation of bone morphogenic protein 3 (*BMP3*) and 6 (*BMP6*) and downregulation of frizzled related protein (*FRZB*) and growth differentiation factor 10 (*GDF10*). In another large transcriptomic analysis study, RNA-seq was performed on paired preserved and lesioned cartilage of 124 OA patients [64]. Differentially expressed genes found in this study were enriched for, amongst others, cytokine activity, characterized by upregulation of cytokine receptor like factor 1 (*CRLF1*), *IL11*, and *IL1- $\beta$* , suggesting OA-related inflammation is driven by the interleukin 6 (IL6) super family (**Table 2**).

While valuable extensive effort has been made to characterize the pathophysiological process in articular cartilage, the pathophysiology of underlying subchondral bone is less explored. This despite the fact that there is accumulating evidence that subchondral bone, in interaction with articular cartilage, contributes to both OA onset and progression [24, 27, 65, 66]. Chou and colleagues used microarray analysis to identify differentially expressed genes between OA and non-OA subchondral bone [62]. Among the differentially expressed genes were *TNF*, collagen type 12 alpha 1 (*COL12A1*), sclerostin (*SOST*), bone morphogenic protein 7 (*BMP7*), and chordin-like 2 (*CHRD2*) (**Table 2**). Another study used microarray analysis to identify differential expression of genes between OA bone marrow lesion and control bone samples [67]. They found genes involved in osteochondral turnover, neurogenesis, and inflammation. However, both of these studies only included knee samples and in both studies microarray analysis was performed. The disadvantage of microarray analysis is that it only profiles predefined genes, while RNA-seq, for example, results in transcriptome-wide gene expression profiling. Therefore, valuable information might be missed by microarray analysis

### *Characterization of OA subtypes*

Recently, OA is more recognized to be a heterogeneous disease with variable characteristics across OA patients. For that matter, transcriptomic analysis of articular cartilage can also be used to identify OA subtypes to better understand heterogeneity of the underlying molecular disease process. Yuan and colleagues identified four subtypes of knee OA by performing unsupervised clustering based on top 4000 genes that showed highest variation across patients [70]. These four subtypes represented GAG metabolic disorder, collagen metabolic disorder, activated sensory neurons, and inflammation. In another study, two OA subtypes were identified also in knee OA samples [71]. These two subtypes were associated to chondrocyte hypertrophy and immune response,

Table 2 – Differential expression between macroscopically preserved and lesioned OA articular cartilage and subchondral bone.

| Articular Cartilage         |                  |             |          |                      |                                       |  |
|-----------------------------|------------------|-------------|----------|----------------------|---------------------------------------|--|
| Pathway                     | Gene             | Fold change | FDR      | Reference FC and FDR | Similar direction of effect shown by: |  |
| Extracellular matrix        | <i>POSTN</i>     | 2.04        | 3.4E-02  | [63]                 | [64, 68]                              |  |
|                             | <i>TNFRSF11B</i> | 3.01        | 7.1E-12  | [63]                 | [61, 64, 68]                          |  |
|                             | <i>SPP1</i>      | 3.14        | 9.0E-07  | [63]                 | [61, 64]                              |  |
| Skeletal system development | <i>BMP3</i>      | 0.28        | 2.9E-03  | [63]                 | [69]                                  |  |
|                             | <i>BMP6</i>      | 2.43        | 1.6E-09  | [63]                 | [61]                                  |  |
|                             | <i>FRZB</i>      | 0.27        | 1.9E-09  | [63]                 | [61, 64, 68]                          |  |
|                             | <i>GDF10</i>     | 0.35        | 1.0E-08  | [63]                 | [61, 64, 68]                          |  |
| Cytokine activity           | <i>IL11</i>      | 22.79       | 1.6E-20  | [63]                 | [64, 68]                              |  |
|                             | <i>CRLF1</i>     | 3.04        | 3.0E-10  | [63]                 | [61, 64, 68]                          |  |
| Subchondral bone            |                  |             |          |                      |                                       |  |
| Pathway                     | Gene             | Fold change | FDR      | Reference FC and FDR | Similar direction of effect shown by: |  |
| Bone mineral density        | <i>SOST</i>      | 2.51        | 2.59E-04 | [62]                 | -                                     |  |
| Abnormal bone morphology    | <i>COL12A1</i>   | 2.26        | 6.55E-08 | [62]                 | -                                     |  |
| Mineralization of cells     | <i>TNF</i>       | 0.32        | 1.17E-08 | [62]                 | -                                     |  |
|                             | <i>BMP7</i>      | 0.40        | 1.65E-09 | [62]                 | -                                     |  |
|                             | <i>CHRD12</i>    | 0.25        | 1.40E-04 | [62]                 | -                                     |  |

respectively. Recently, Coutinho de Almeida and colleagues also identified two OA subtypes using RNA-seq data of both hip and knee OA samples, representing similar processes [72]. More importantly, they showed that these subtypes were associated with phenotypic differences. Identification of these OA subtypes enables better predictions of clinical outcomes of OA treatments [70]. However, to distinguish OA subtypes in clinical practice, non-invasive biomarkers are necessary to stratify patients on OA subtype before treatments start.

### *Allelic imbalanced expression*

While some OA risk variants are missense mutations located in the protein-coding region of a gene and thereby directly affecting protein structure, most SNPs conferring risk to OA are located in non-coding regions. Functional follow-up studies have shown that SNPs in non-coding regions frequently act via altered expression of positional genes in *cis*, also known as allelic imbalanced expression (AIE) [73, 74]. Transcriptomic data can also be used to screen for allelic imbalance. In this respect, den Hollander and colleagues used RNA-seq data of preserved and lesioned OA articular cartilage to screen for transcriptome-wide AIE [42]. As a result, 2,070 SNPs were identified marking AIE of 1,031 genes, including 18 genes that were also identified as OA susceptibility genes in GWASs. Among these 18 genes were *WWP2*, *FRZB*, and matrix gla protein (*MGP*) identified as highly significant. More recently, Coutinho de Almeida and colleagues also screened for AIE in both articular cartilage and subchondral bone OA samples [75]. In this study, 26 SNPs were identified being subjected to AIE in cartilage, and 7 SNPs were identified in subchondral bone. These studies on AIE are extremely valuable as they can be used to make firm hypothesis on the direction of effect of identified compelling OA risk genes. However, for translation of these OA risk genes towards development of disease modifying OA treatments, functional follow-up studies are required to elucidate molecular mechanisms and targets of these genes [76-78].


### **Epigenetics in osteoarthritis**

Epigenetics refers to changes in heritable phenotype without alterations in the genetic code. Epigenetic regulation provides cells with a mechanism to respond to environmental cues such as mechanical stress and microtraumas by changing gene and protein expression levels temporarily [79]. Epigenetic mechanisms include DNA methylation, histone modification, and non-coding RNA expression, all being extensively associated to OA pathophysiology [80].

### *DNA methylation and histone modifications*

DNA consist of a sequence of adenine, thymine, cytosine, and guanine and cytosine followed by guanine, is called a CpG site. In a CpG site, the cytosine can be converted

to 5-methylcytosine (5mC) by methylation catalyzed by methyltransferases. This process is called DNA methylation and this process alters the binding of proteins, such as transcription factors, to the DNA and therefore it changes gene expression levels (**Figure 4A**) [81]. DNA is condensed around histone proteins (H3, H4, H2A, and H2B). To modulate gene expression, histone proteins undergo modifications such as methylation and acetylation (**Figure 4B**) [82, 83]. Histone methylation mainly inhibits gene transcription by blocking binding of transcription factors, while histone acetylation is associated with increased gene transcription. Histone modifications are executed by histone methyl transferases, histone acetyl transferases, histone deacetylases, and histone demethylases [80].



**Figure 4 – Overview of epigenetic processes.**

(A) overview of DNA methylation. Methylation of the DNA alters the binding of proteins, such as transcription factors, to the DNA (created with Biorender.com) (B) Schematic overview of histone modifications. Methylation of histones is associated with decreased gene transcription, while acetylation of histones is associated with increased gene transcription (created with Biorender.com)


### *MicroRNA expression*

While DNA methylation and histone modifications are mainly regulating transcription of genes, non-coding RNAs are a class of transcriptional and (post-)translational regulators. Non-coding RNAs are classified based on their size in micro-RNAs (miRNAs) and long non-coding RNAs (lncRNAs). MiRNAs are typically between 18 and 25 nucleotides in length and they negatively regulate translation of mRNA to protein. Most miRNAs bind to the 3' untranslated region (UTR) of their target mRNA, thereby inhibiting translation and/or reducing mRNA stability [84, 85]. The number of base pairs that overlap between miRNAs and their target mRNA determine whether the mRNA is degraded via Argonaute RISC Catalytic Component 2 (Ago2) or repressed via Argonaute RISC Catalytic Component 1 (Ago1). The target mRNA will be degraded when there is (almost) a perfect overlap between miRNA and target mRNA, while translation of the target mRNA will be repressed when there is only partial overlap (**Figure 5A**) [86].

As dysregulated miRNAs mark complex diseases, such as OA, multiple studies focused on characterization of miRNA expression and identification of their mRNA targets in OA pathophysiology. To date, the role of miRNAs in OA has mainly been studied in articular cartilage. For example, Iliopoulos and colleagues compared expression levels of 365 miRNAs in cartilage of 33 OA joints and cartilage of 10 non-OA joints [87]. This resulted in the identification of 16 differentially expressed miRNAs, including upregulation of miR-22 and downregulation of miR-140 in OA cartilage. In another study, miRNAs were identified being differentially expressed between OA and non-OA cartilage and bone, including miR-9 and miR-98[88]. Upon gene targeting prediction and pathway analysis, these miRNAs seem to play a role in inflammation. More recently, integration of transcriptome-wide miRNA-seq and mRNA-seq of OA articular cartilage resulted in identification of 143 miRNAs differentially expressed between macroscopically preserved and lesioned OA cartilage [63]. possible mRNA target was identified for 62 of these differentially expressed miRNAs, including *RGS4*. *RGS4* expression was found to be regulated by mir-140, which is abundantly expressed in articular cartilage and known to be involved in chondrogenesis and osteoarthritis [89, 90]. Mir-140 is co-transcribed with its host gene *WWP2* and regulated by *SOX9*. Moreover, miR-140 is shown to be involved in endochondral ossification, as loss of miR-140 expression in mice results in bone defects and malformations [91].

### *Long non-coding RNA expression*

In contrast to miRNAs, lncRNAs are less frequently investigated mainly because of the poor evolutionary conservation between species and because of their generally low expression levels [92, 93]. LncRNAs are typically over 200 nucleotides in length and while lncRNAs lack protein-coding ability, they share similarities with mRNAs, as most lncRNAs have a 5' 7-methylguanosine cap and a 3' poly A tail and are transcribed by RNA polymerase II [94]. LncRNAs are involved in various transcriptional and (post-)translational processes, including chromatin remodeling, mRNA translation, transcription factor activity, and mRNA and protein stability (**Figure 5B**) [95, 96]. Moreover, lncRNA expression can be highly tissue- and disease specific [97]. Multiple lncRNAs have been reported to be involved in chondrogenesis and osteogenesis [93, 98]. Similar to miRNAs, in OA pathophysiology currently lncRNAs have been exclusively studied in articular cartilage. Upon comparing macroscopically preserved and lesioned OA cartilage, 191 lncRNAs were identified to be differentially expressed [99]. Among these differentially expressed lncRNAs was prolyl 3-hydroxylase 2 antisense RNA 1 (*P3H2-AS1*), which was shown to regulate expression levels of its sense gene prolyl 3-hydroxylase 2 (*P3H2*). In another study comparing OA and non-OA articular cartilage, maternally expressed 3 (*MEG3*) was found to be downregulated in both OA hips and knees [100]. As lncRNAs tend to be tissue- and disease specific, identification of



**Figure 5 – Overview of non-coding mode-of-actions.**

(A) Most miRNAs bind to the 3'UTR of their target mRNA, thereby (partly) inhibiting translation to protein (created with Biorender.com). (B) LncRNAs have various mode-of-actions both on a transcriptional, translational, and post-translational level (Created with Biorender.com).

lncRNAs that mark OA pathophysiological processes might bring new opportunities in development of joint tissue- and disease specific therapeutic strategies. Although multiple lncRNAs are identified marking OA in articular cartilage, studies on lncRNAs marking OA pathophysiology in subchondral bone are still lacking.

### *Biomarkers in osteoarthritis*

To date, there are no reliable biomarkers that reflect ongoing processes in joint tissues. Classification and/or diagnosis of OA is therefore only based on imaging (radiography, MRI) and clinical symptoms, such as pain and stiffness of the affected joint [101]. Consequently, early diagnosis of OA, information on OA prognosis, and ability to predict treatment outcomes are still lacking [102]. To overcome this knowledge gap, research started focusing on identification of potential OA biomarkers using relatively easily accessible sites, such as synovial fluid, urine, and blood. For example, Soul and

colleagues identified a set of proteins, including POSTN, TNC, and MGP, that were predicted to be secreted in the synovial fluid. This set of proteins in synovial fluid could reflect whether a patient is subjected to inflammation-driven or chondrocyte hypertrophy-driven OA [71]. Another study identified six proteins in measured in synovial fluid that were in association with synovial inflammation, severity of cartilage loss, and joint pain [103]. These synovial fluid proteins included MMP3 and soluble vascular cell adhesion molecule 1 (sVCAM1). Nonetheless, urine and blood are more easily accessible and therefore less invasive compared to synovial fluid. OA biomarkers that can be measured in urine are mostly based on breakdown products of main cartilage components collagen type 2 (COL2) and aggrecan (ACAN) [104]. For instance, urinary levels of C-terminal crosslinking telopeptide of type II collagen (CTX-II) are shown to be associated with radiographic signs of OA in multiple studies [105, 106]. Moreover, CTX-II were higher in OA patients compared to healthy controls [107]. Nevertheless, these levels are solely reflecting collagen type II breakdown and do not provide insight in other ongoing OA-related processes. Recently, circulating miRNAs gained interest and Ramos and colleagues showed for the first time that miRNA expression levels in plasma could reflect changes in mRNA expression patterns in articular cartilage [108]. They identified 7 miRNAs, including miR-140-3p, miR-181a-3p, and miR-4443, that were able to predict OA progression. In another study, circulating miR-140-3p, miR-33b-3p, and miR-671-3p were identified in serum as OA biomarker and reflecting metabolic processes in articular cartilage [109]. Finally, Murata and colleagues identified miR-132 being predictive for rheumatoid arthritis and OA [110].

### ***In vitro* osteoarthritis disease models**

To study compelling OA risk genes appropriate *in vitro* human OA disease models are required that incorporate disease relevant tissues, e.g. bone and cartilage [111]. To date, available *in vitro* model systems for osteochondral tissues include 2D cell cultures, 3D pellet cultures, 3D multi tissue co-cultures (**Figure 6**).

#### *2D cell cultures*

The simplest *in vitro* models are 2D cell cultures of OA relevant cells, such as chondrocytes, bone-marrow derived mesenchymal stromal cells (hBMSCs), osteoblasts, osteocytes, and osteoclasts. These 2D cell cultures can be exposed to OA-related cytokines or to conditioned media to study their cellular response [112]. For example in the study of Van Geffen and colleagues [113], human chondrocytes were cultured in 2D and exposed to IL1- $\beta$ , TNF- $\alpha$ , or human OA synovium-conditioned medium to study the effect of inflammation on interleukin 37 (*IL37*) expression levels. To incorporate intercellular communication in 2D cell cultures co-cultures can be performed in Transwells, for example to study intercellular communication between chondrocytes and bone




Figure 6 – Overview of OA relevant cells and some available OA models.

cells [114]. While being a useful tool, Transwell co-cultures still lack complexity and interaction of the ECM, and it is known that cells are prone to lose their specific phenotype on 2D surfaces [115].

### 3D pellet cultures

To include the effect of extracellular matrix and minimize dedifferentiation of cells, 3D cell pellet cultures or micro mass cultures are extensively used to model cartilaginous and osseous tissue [116, 117]. Caron and colleagues showed that chondrocytes in 3D pellet cultures are less prone to become hypertrophic compared to 2D cell cultures [115]. On another level, Bömer and colleagues showed that DNA methylation profile was 99% similar between 3D human chondrocyte pellet cultures and autologous articular cartilage [118]. Subsequently, these 3D human chondrocyte pellet cultures were used to study the effect of silencing OA risk gene fibronectin (*FN1*) [119]. In this study, it was shown that downregulation of *FN1* had detrimental effects on cartilage matrix deposition. These changes in cartilage matrix deposition can only be shown in 3D structures as no ECM is produced by 2D cell cultures, further stressing the advantage of using 3D model systems. In another study, lentiviral particle-mediated overexpression of *TNFRSF11B* in 3D human chondrocyte pellet cultures resulted in enhanced chondrocyte to osteoblast transition, thereby underscoring the role of *TNFRSF11B* in OA development [120]. Altogether, these studies show that 3D chondrocyte cell pellet are a suitable and valuable model for OA articular cartilage.

### *Multi-tissue culture systems*

Given the tissue cross-talk, however, translation of strong OA risk genes towards their underlying mechanism is ideally performed in *in vitro* models that incorporate at least functional bone and cartilage tissue units. Therefore, human osteochondral explants might be an alternative. Osteochondral explants are directly derived from patient material and the main advantage is that cells maintain their natural aged 3D environment [121]. Houtman and colleagues explored the response of osteochondral explants upon exposure to IL1- $\beta$ , triiodothyronine (T3), and 65% mechanical strain, and confirmed suitability of osteochondral explants as OA models for inflammation, hypertrophy, and posttraumatic OA, respectively [122]. Subsequently, the posttraumatic OA model was used to study potential pharmacological OA treatment with deiodinase inhibitor iopanoic acid (IOP), an FDA approved medication [123]. OA susceptibility gene *DIO2* encodes Iodothyronine deiodinase type 2 enzyme (D2), which is known to convert thyroxine (T4) to T3, thereby inducing hypertrophy [40]. IOP is known to inhibit D2 activity and therefore IOP was hypothesized to be a potential OA treatment. Upon exposing osteochondral explants to 65% mechanical strain to induce posttraumatic OA, with and without IOP treatment, Houtman and colleagues showed that IOP treatment was able to prevent posttraumatic OA-related changes in articular cartilage [123]. Together, these studies show that osteochondral explants provide major advantages in studying potential disease modifying OA treatments using a reliable human biomimetic model and complying to the principle of reduction, refinement, and replacement of animal models. Yet, use of osteochondral explants limits scalability as collection of explants is dependent on patients undergoing joint replacement surgery. Moreover, long-term cultures of osteochondral explants might be challenging, as their properties change over time [112]. Finally, genetic manipulation such as upregulation or silencing of genes cannot be performed in osteochondral explants, limiting these models to study OA related perturbations and treatment options. Henceforth, more state-of-the-art model systems are needed that are based on microfluidic tissue-on-chip principles.

Lin and colleagues developed a microfluidic osteochondral system that consists of a chondrogenic and osteogenic microenvironment [124]. Human bone marrow derived stem cells (hBMSCs) were seeded in hydrogels in these two compartments and chondrogenesis and osteogenesis was induced. More recently, to overcome the limited availability of hBMSCs, the same system was used to create osteochondral tissues using induced pluripotent stem cells (iPSCs) [125]. These iPSCs were first differentiated towards induced mesenchymal stem cells (iMSC) and these iMSCs were seeded in hydrogels. Upon culturing these hydrogels for 28 days within the microfluidic chip, the two compartments showed a chondrogenic and osteogenic phenotype, respectively. Subsequently, joint inflammation was mimicked by exposing the chondrogenic compartment to IL1- $\beta$  and this inflammation was then treated by addition of anti-

inflammatory drug Celecoxib. Even though this system represents an elegant manner to study disease mechanisms and response to disease modifying OA drugs, the use of hydrogels has some disadvantages. Hydrogels require crosslinking methods, such as temperature changes, UV exposure, or enzymatic crosslinking, to form a stable network [126]. These crosslinking methods often are known to negatively affect cells, adding an uncertainty to the model. Moreover, hydrogels still fail to accurately mimic the 3D joint environment and reoccurring problems using hydrogels are formation of matrix islands and limited cell proliferation within hydrogels, which occur because of the elastic nature of the material [127]. Furthermore, tissue damage cannot be studied using hydrogels. Consequently, there are still shortcomings to bridge towards development of osteochondral constructs-on-a-chip consisting of biological ECM instead of hydrogels.

### Outline of this thesis

In this thesis, we tried to make a step forward in transition from bench-to-bedside in OA by combining transcriptomic data from OA articular cartilage, subchondral bone, and plasma, with previously reported genetic studies, and OA disease modelling. In **chapter 2** and **chapter 3** we used RNA-sequencing data of subchondral bone to identify genes and lncRNAs that mark OA pathophysiology, by comparing macroscopically preserved and lesioned OA subchondral bone. Subsequently, we integrated these findings with previously reported findings on articular cartilage (partially of same patients) and genetics to identify potential druggable targets with possibly effects in both tissues.

In **chapter 4** and **chapter 5** we gained more insight in previously identified OA molecular endotypes in articular cartilage. To make OA molecular endotypes applicable to clinical practice, we first identified non-invasive biomarkers in plasma that allow stratification of patients based on their endotype before treatment (**chapter 4**). These OA molecular endotypes were identified based on articular cartilage, leaving the underlying subchondral bone unexplored. Therefore, we used RNA-sequencing data of the underlying subchondral bone to characterize these OA molecular endotypes in bone by performing differential expression analysis between these endotypes (**chapter 5**).

To translate genetic findings towards OA drug development, functional investigation is necessary to unravel underlying biological mechanisms of how these OA risk genes affect articular cartilage and/or subchondral bone matrix deposition. As proof-of-concept, in **chapter 6** and **chapter 7** we functionally investigated *WWP2* and *IL11* in two different models of joint tissue. The effect of *WWP2* upregulation on cartilage matrix deposition was explored using 3D human chondrocyte pellet cultures (**chapter 6**), while the effects of hrIL11 on both articular cartilage and subchondral bone were explored using osteochondral explant cultures (**chapter 7**).

Finally, we developed a new *in vitro* biomimetic model system representing functional articular cartilage and subchondral bone to study OA-related perturbations and/or OA susceptibility genes (**chapter 8**). This osteochondral-unit-on-a-chip allows in depth investigations of underlying mechanisms of OA risk genes in both tissues.

## References

- Hunter, D.J., L. March, and M. Chew, *Osteoarthritis in 2020 and beyond: a Lancet Commission*. Lancet, 2020. **396**(10264): p. 1711-1712.
- Safiri, S., et al., *Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017*. Annals of the Rheumatic Diseases, 2020. **79**(6): p. 819.
- Loeser, R.F., et al., *Osteoarthritis: a disease of the joint as an organ*. Arthritis Rheum, 2012. **64**(6): p. 1697-707.
- Marshall, M., et al., *Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management*. Nature Reviews Rheumatology, 2018. **14**(11): p. 641-656.
- Katz, J.N., K.R. Arant, and R.F. Loeser, *Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review*. JAMA, 2021. **325**(6): p. 568-578.
- Litwic, A., et al., *Epidemiology and burden of osteoarthritis*. Br Med Bull, 2013. **105**: p. 185-99.
- Woolf, A.D., J. Erwin, and L. March, *The need to address the burden of musculoskeletal conditions*. Best Pract Res Clin Rheumatol, 2012. **26**(2): p. 183-224.
- Johnson, V.L. and D.J. Hunter, *The epidemiology of osteoarthritis*. Best Practice & Research Clinical Rheumatology, 2014. **28**(1): p. 5-15.
- Palazzo, C., et al., *Risk factors and burden of osteoarthritis*. Annals of Physical and Rehabilitation Medicine, 2016. **59**(3): p. 134-138.
- Spector, T.D. and A.J. MacGregor, *Risk factors for osteoarthritis: genetics*11Supported by Procter & Gamble Pharmaceuticals, Mason, OH. Osteoarthritis and Cartilage, 2004. **12**: p. 39-44.
- Mackie, E.J., et al., *Endochondral ossification: How cartilage is converted into bone in the developing skeleton*. The International Journal of Biochemistry & Cell Biology, 2008. **40**(1): p. 46-62.
- Berendsen, A.D. and B.R. Olsen, *Bone development*. Bone, 2015. **80**: p. 14-18.
- Sophia Fox, A.J., A. Bedi, and S.A. Rodeo, *The basic science of articular cartilage: structure, composition, and function*. Sports health, 2009. **1**(6): p. 461-468.
- Bhosale, A.M. and J.B. Richardson, *Articular cartilage: structure, injuries and review of management*. British Medical Bulletin, 2008. **87**(1): p. 77-95.
- van der Kraan, P.M. and W.B. van den Berg, *Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration?* Osteoarthritis and Cartilage, 2012. **20**(3): p. 223-232.
- Dreier, R., *Hypertrophic differentiation of chondrocytes in osteoarthritis: the developmental aspect of degenerative joint disorders*. Arthritis Res Ther, 2010. **12**(5): p. 216.
- Goldring, M.B. and K.B. Marcu, *Cartilage homeostasis in health and rheumatic diseases*. Arthritis Research & Therapy, 2009. **11**(3): p. 224.
- Goldring, M.B. and S.R. Goldring, *Osteoarthritis*. J Cell Physiol, 2007. **213**(3): p. 626-34.
- Xiao, Z.F., et al., *Cartilage degradation in osteoarthritis: A process of osteochondral remodeling resembles the endochondral ossification in growth plate?* Med Hypotheses, 2018. **121**: p. 183-187.
- Li, G., et al., *Subchondral bone in osteoarthritis: insight into risk factors and microstructural changes*. Arthritis Research & Therapy, 2013. **15**(6): p. 223.
- Karsdal, M.A., et al., *The coupling of bone and cartilage turnover in osteoarthritis: opportunities for bone antiresorptives and anabolics as potential treatments?* Ann Rheum Dis, 2014. **73**(2): p. 336-48.
- Zhu, X., et al., *Subchondral Bone Remodeling: A Therapeutic Target for Osteoarthritis*. Frontiers in cell and developmental biology, 2021. **8**: p. 607764-607764.
- Madry, H., C.N. van Dijk, and M. Mueller-Gerbl, *The basic science of the subchondral bone*. Knee Surgery, Sports Traumatology, Arthroscopy, 2010. **18**(4): p. 419-433.
- Funck-Brentano, T. and M. Cohen-Solal, *Crosstalk between cartilage and bone: when bone cytokines matter*. Cytokine Growth Factor Rev, 2011. **22**(2): p. 91-7.
- Funck-Brentano, T. and M. Cohen-Solal, *Subchondral bone and osteoarthritis*. Curr Opin Rheumatol, 2015. **27**(4): p. 420-6.
- Goldring, M.B. and S.R. Goldring, *Articular cartilage and subchondral bone in the pathogenesis of osteoarthritis*. Ann N Y Acad Sci, 2010. **1192**: p. 230-7.
- Goldring, S.R. and M.B. Goldring, *Changes in the osteochondral unit during osteoarthritis: structure, function and cartilage-bone crosstalk*. Nat Rev Rheumatol, 2016. **12**(11): p. 632-644.
- Boer, C.G., et al., *Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations*. Cell, 2021.
- Styrkarsdottir, U., et al., *Whole-genome sequencing identifies rare genotypes in COMP and CHADL associated with high risk of hip osteoarthritis*. Nat Genet, 2017. **49**(5): p. 801-805.
- Zengini, E., et al., *Genome-wide analyses using UK Biobank data provide insights into the genetic architecture of osteoarthritis*. Nat Genet, 2018. **50**(4): p. 549-558.
- Styrkarsdottir, U., et al., *Meta-analysis of Icelandic and UK data sets identifies missense variants in SMO, IL11, COL11A1 and 13 more new loci associated with osteoarthritis*. Nat Genet, 2018. **50**(12): p. 1681-1687.
- Tachmazidou, I., et al., *Identification of new therapeutic targets for osteoarthritis through genome-wide analyses of UK Biobank data*. Nat Genet, 2019. **51**(2): p. 230-236.
- Zeggini, E., et al., *Identification of new susceptibility loci for osteoarthritis (arcOGEN): a genome-wide association study*. Lancet, 2012. **380**(9844): p. 815-23.
- Uffelmann, E., et al., *Genome-wide association studies*. Nature Reviews Methods Primers, 2021. **1**(1): p. 59.
- Aubourg, G., et al., *Genetics of osteoarthritis*. Osteoarthritis and Cartilage, 2021.
- Kespohl, B., et al., *The cytokine interleukin-11 crucially links bone formation, remodeling and resorption*. Cytokine & Growth Factor Reviews, 2021. **60**: p. 18-27.

37. Valdes, A.M., et al., *Genetic variation in the SMAD3 gene is associated with hip and knee osteoarthritis*. Arthritis Rheum, 2010. **62**(8): p. 2347-52.
38. *The Genotype-Tissue Expression (GTEx) project*. Nat Genet, 2013. **45**(6): p. 580-5.
39. Yang, X., et al., *TGF-beta/Smad3 signals repress chondrocyte hypertrophic differentiation and are required for maintaining articular cartilage*. J Cell Biol, 2001. **153**(1): p. 35-46.
40. Meulenbelt, I., et al., *Identification of DIO2 as a new susceptibility locus for symptomatic osteoarthritis*. Human Molecular Genetics, 2008. **17**(12): p. 1867-1875.
41. Bomer, N., et al., *Underlying molecular mechanisms of DIO2 susceptibility in symptomatic osteoarthritis*. Ann Rheum Dis, 2015. **74**(8): p. 1571-9.
42. den Hollander, W., et al., *Annotating Transcriptional Effects of Genetic Variants in Disease-Relevant Tissue: Transcriptome-Wide Allelic Imbalance in Osteoarthritic Cartilage*. Arthritis Rheumatol, 2019. **71**(4): p. 561-570.
43. Hasegawa, M., T. Yoshida, and A. Sudo, *Tenascin-C in Osteoarthritis and Rheumatoid Arthritis*. Frontiers in Immunology, 2020. **11**.
44. Meng, W., et al., *Genome-wide association study of knee pain identifies associations with GDF5 and COL27A1 in UK Biobank*. Commun Biol, 2019. **2**: p. 321.
45. Hjorten, R., et al., *Type XXVII collagen at the transition of cartilage to bone during skeletogenesis*. Bone, 2007. **41**(4): p. 535-42.
46. Evangelou, E., et al., *Large-scale analysis of association between GDF5 and FRZB variants and osteoarthritis of the hip, knee, and hand*. Arthritis Rheum, 2009. **60**(6): p. 1710-21.
47. Chapman, K., et al., *A meta-analysis of European and Asian cohorts reveals a global role of a functional SNP in the 5' UTR of GDF5 with osteoarthritis susceptibility*. Hum Mol Genet, 2008. **17**(10): p. 1497-504.
48. Kania, K., et al., *Regulation of Gdf5 expression in joint remodelling, repair and osteoarthritis*. Sci Rep, 2020. **10**(1): p. 157.
49. Nakamura, Y., et al., *Wwp2 is essential for palatogenesis mediated by the interaction between Sox9 and mediator subunit 25*. Nat Commun, 2011. **2**: p. 251.
50. Houtman, E., et al., *Characterization of dynamic changes in Matrix Gla Protein (MGP) gene expression as function of genetic risk alleles, osteoarthritis relevant stimuli, and the vitamin K inhibitor warfarin*. Osteoarthritis and Cartilage, 2021. **29**(8): p. 1193-1202.
51. den Hollander, W., et al., *Genome-wide association and functional studies identify a role for matrix Gla protein in osteoarthritis of the hand*. 2017. **76**(12): p. 2046-2053.
52. Misra, D., et al., *Matrix Gla protein polymorphism, but not concentrations, is associated with radiographic hand osteoarthritis*. The Journal of rheumatology, 2011. **38**(9): p. 1960-1965.
53. Usmani, S.E., et al., *Context-specific protection of TGFα null mice from osteoarthritis*. Sci Rep, 2016. **6**: p. 30434.
54. Usmani, S.E., et al., *Transforming growth factor alpha controls the transition from hypertrophic cartilage to bone during endochondral bone growth*. Bone, 2012. **51**(1): p. 131-41.
55. Styrkarsdottir, U., et al., *Severe osteoarthritis of the hand associates with common variants within the ALDH1A2 gene and with rare variants at 1p31*. Nat Genet, 2014. **46**(5): p. 498-502.
56. Hafez, A., et al., *Col11a1 Regulates Bone Microarchitecture during Embryonic Development*. J Dev Biol, 2015. **3**(4): p. 158-176.
57. Loughlin, J., et al., *Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females*. Proc Natl Acad Sci U S A, 2004. **101**(26): p. 9757-62.
58. Leijten, J.C., et al., *GREM1, FRZB and DKK1 mRNA levels correlate with osteoarthritis and are regulated by osteoarthritis-associated factors*. Arthritis Res Ther, 2013. **15**(5): p. R126.
59. Lories, R.J., et al., *Articular cartilage and biomechanical properties of the long bones in Frzb-knockout mice*. Arthritis Rheum, 2007. **56**(12): p. 4095-103.
60. Enomoto-Iwamoto, M., et al., *The Wnt antagonist Frzb-1 regulates chondrocyte maturation and long bone development during limb skeletogenesis*. Dev Biol, 2002. **251**(1): p. 142-56.
61. Ramos, Y.F., et al., *Genes involved in the osteoarthritis process identified through genome wide expression analysis in articular cartilage; the RAAK study*. PLoS One, 2014. **9**(7): p. e103056.
62. Chou, C.H., et al., *Genome-wide expression profiles of subchondral bone in osteoarthritis*. Arthritis Res Ther, 2013. **15**(6): p. R190.
63. Coutinho de Almeida, R., et al., *RNA sequencing data integration reveals an miRNA interactome of osteoarthritis cartilage*. Ann Rheum Dis, 2019. **78**(2): p. 270-277.
64. Katsoula, G., et al., *A molecular map of long non-coding RNA expression, isoform switching and alternative splicing in osteoarthritis*. Human Molecular Genetics, 2022: p. ddac017.
65. Fellows, C.R., C. Matta, and A. Mobasheri, *Applying Proteomics to Study Crosstalk at the Cartilage-Subchondral Bone Interface in Osteoarthritis: Current Status and Future Directions*. EBioMedicine, 2016. **11**: p. 2-4.
66. Pan, J., et al., *Elevated cross-talk between subchondral bone and cartilage in osteoarthritic joints*. Bone, 2012. **51**(2): p. 212-7.
67. Kuttapitiya, A., et al., *Microarray analysis of bone marrow lesions in osteoarthritis demonstrates upregulation of genes implicated in osteochondral turnover, neurogenesis and inflammation*. Ann Rheum Dis, 2017. **76**(10): p. 1764-1773.
68. Dunn, S.L., et al., *Gene expression changes in damaged osteoarthritic cartilage identify a signature of non-chondrogenic and mechanical responses*. Osteoarthritis Cartilage, 2016. **24**(8): p. 1431-40.
69. Li, H., et al., *Whole-transcriptome sequencing of knee joint cartilage from osteoarthritis patients*. Bone Joint Res, 2019. **8**(7): p. 290-303.
70. Yuan, C., et al., *Classification of four distinct osteoarthritis subtypes with a knee joint tissue transcriptome atlas*. Bone Research, 2020. **8**(1): p. 38.
71. Soul, J., et al., *Stratification of knee osteoarthritis: two major patient subgroups identified by genome-wide expression analysis of articular cartilage*. Ann Rheum Dis, 2018. **77**(3): p. 423.
72. Coutinho de Almeida, R., et al., *Identification and characterization of two consistent osteoarthritis subtypes by transcriptome and clinical data integration*. Rheumatology (Oxford), 2020.
73. Raine, E.V., et al., *Allelic expression analysis of the osteoarthritis susceptibility gene COL11A1 in human joint tissues*. BMC Musculoskelet Disord, 2013. **14**: p. 85.
74. Gee, F., et al., *Allelic expression analysis of the osteoarthritis susceptibility locus that maps to chromosome 3p21 reveals cis-acting eQTLs at GNL3 and SPCS1*. BMC Med Genet, 2014. **15**: p. 53.
75. Coutinho de Almeida, R., et al., *Allelic expression imbalance in articular cartilage and subchondral bone refined genome-wide association signals in osteoarthritis*. medRxiv, 2022: p. 2022.04.07.22273552.
76. Loughlin, J., *Translating osteoarthritis genetics research: challenging times ahead*. Trends in Molecular Medicine, 2022. **28**(3): p. 176-182.
77. Ramos, Y.F.M. and I. Meulenbelt, *Implementation of Functional Genomics for Bench-to-Bedside Transition in*

- Osteoarthritis. *Current Rheumatology Reports*, 2015. 17(8): p. 53.
78. Bomer, N., et al., Translating genomics into mechanisms of disease: Osteoarthritis. *Best Pract Res Clin Rheumatol*, 2015. 29(6): p. 683-91.
79. Coutinho de Almeida, R., Y.F.M. Ramos, and I. Meulenbelt, Involvement of epigenetics in osteoarthritis. *Best Pract Res Clin Rheumatol*, 2017. 31(5): p. 634-648.
80. Ramos, Y.F. and I. Meulenbelt, The role of epigenetics in osteoarthritis: current perspective. *Curr Opin Rheumatol*, 2017. 29(1): p. 119-129.
81. den Hollander, W. and I. Meulenbelt, DNA Methylation in Osteoarthritis. *Curr Genomics*, 2015. 16(6): p. 419-26.
82. Letarouilly, J.-G., O. Broux, and A. Clabaut, New insights into the epigenetics of osteoporosis. *Genomics*, 2019. 111(4): p. 793-798.
83. Park, J., et al., The role of histone modifications: from neurodevelopment to neurodegenerative diseases. *Signal Transduction and Targeted Therapy*, 2022. 7(1): p. 217.
84. Bartel, D.P., MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell*, 2004. 116(2): p. 281-97.
85. Swingle, T.E., et al., The function of microRNAs in cartilage and osteoarthritis. *Clin Exp Rheumatol*, 2019. 37 Suppl 120(5): p. 40-47.
86. Le, L.T.T., T.E. Swingle, and I.M. Clark, Review: The Role of MicroRNAs in Osteoarthritis and Chondrogenesis. *Arthritis & Rheumatism*, 2013. 65(8): p. 1963-1974.
87. Iliopoulos, D., et al., Integrative microRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks. *PLoS One*, 2008. 3(11): p. e3740.
88. Jones, S.W., et al., The identification of differentially expressed microRNA in osteoarthritic tissue that modulate the production of TNF- $\alpha$  and MMP13. *Osteoarthritis and Cartilage*, 2009. 17(4): p. 464-472.
89. Yang, J., et al., MiR-140 is co-expressed with Wwp2-C transcript and activated by Sox9 to target Sp1 in maintaining the chondrocyte proliferation. *FEBS Lett*, 2011. 585(19): p. 2992-7.
90. Endisha, H., et al., The complex landscape of microRNAs in articular cartilage: biology, pathology, and therapeutic targets. *JCI Insight*, 2018. 3(17).
91. Nakamura, Y., et al., Chondrocyte-specific microRNA-140 regulates endochondral bone development and targets Dnpep to modulate bone morphogenetic protein signaling. *Mol Cell Biol*, 2011. 31(14): p. 3019-28.
92. Rice, S.J., et al., Interplay between genetics and epigenetics in osteoarthritis. *Nature Reviews Rheumatology*, 2020. 16(5): p. 268-281.
93. Ghafouri-Fard, S., et al., The Emerging Role of Non-Coding RNAs in Osteoarthritis. *Frontiers in Immunology*, 2021. 12.
94. Marchese, F.P., I. Raimondi, and M. Huarte, The multidimensional mechanisms of long noncoding RNA function. *Genome Biology*, 2017. 18(1): p. 206.
95. Statello, L., et al., Gene regulation by long non-coding RNAs and its biological functions. *Nature Reviews Molecular Cell Biology*, 2021. 22(2): p. 96-118.
96. Morlando, M., M. Ballarino, and A. Fatica, Long Non-Coding RNAs: New Players in Hematopoiesis and Leukemia. *Frontiers in medicine*, 2015. 2: p. 23-23.
97. Quinn, J.J. and H.Y. Chang, Unique features of long non-coding RNA biogenesis and function. *Nature Reviews Genetics*, 2016. 17(1): p. 47-62.
98. Sun, H., et al., Emerging roles of long noncoding RNA in chondrogenesis, osteogenesis, and osteoarthritis. *Am J Transl Res*, 2019. 11(1): p. 16-30.
99. van Hoolwerf, M., et al., Elucidating Epigenetic Regulation by Identifying Functional cis-Acting Long Noncoding RNAs and Their Targets in Osteoarthritic Articular Cartilage. *Arthritis Rheumatol*, 2020. 72(11): p. 1845-1854.
100. Ajekigbe, B., et al., Identification of long non-coding RNAs expressed in knee and hip osteoarthritic cartilage. *Osteoarthritis Cartilage*, 2019. 27(4): p. 694-702.
101. Bernotiene, E., et al., Emerging Technologies and Platforms for the Immunodetection of Multiple Biochemical Markers in Osteoarthritis Research and Therapy. *Frontiers in Medicine*, 2020. 7.
102. Hunter, D.J., et al., Biomarkers for osteoarthritis: current position and steps towards further validation. *Best practice & research. Clinical rheumatology*, 2014. 28(1): p. 61-71.
103. Haraden, C.A., et al., Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation. *Arthritis Research & Therapy*, 2019. 21(1): p. 146.
104. Bay-Jensen, A.C., et al., Blood and urine biomarkers in osteoarthritis – an update on cartilage associated type II collagen and aggrecan markers. *Current Opinion in Rheumatology*, 2022. 34(1).
105. Cheng, H., et al., C-Terminal Cross-Linked Telopeptides of Type II Collagen as Biomarker for Radiological Knee Osteoarthritis: A Meta-Analysis. *Cartilage*, 2020. 11(4): p. 512-520.
106. Meulenbelt, I., et al., Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study. *Annals of the rheumatic diseases*, 2006. 65(3): p. 360-365.
107. Arunrukthavon, P., et al., Can urinary CTX-II be a biomarker for knee osteoarthritis? *Arthroplasty*, 2020. 2(1): p. 6.
108. Ramos, Y.F.M., et al., Circulating MicroRNAs Highly Correlate to Expression of Cartilage Genes Potentially Reflecting OA Susceptibility-Towards Identification of Applicable Early OA Biomarkers. *Biomolecules*, 2021. 11(9): p. 1356.
109. Ntoumou, E., et al., Serum microRNA array analysis identifies miR-140-3p, miR-33b-3p and miR-671-3p as potential osteoarthritis biomarkers involved in metabolic processes. *Clin Epigenetics*, 2017. 9: p. 127.
110. Murata, K., et al., Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. *Arthritis Res Ther*, 2010. 12(3): p. R86.
111. Alexander, P.G., et al., Three-dimensional osteogenic and chondrogenic systems to model osteochondral physiology and degenerative joint diseases. *Exp Biol Med (Maywood)*, 2014. 239(9): p. 1080-95.
112. Piluso, S., et al., Mimicking the Articular Joint with In Vitro Models. *Trends Biotechnol*, 2019. 37(10): p. 1063-1077.
113. van Geffen, E.W., et al., IL37 dampens the IL1 $\beta$ -induced catabolic status of human OA chondrocytes. *Rheumatology*, 2017. 56(3): p. 351-361.
114. Carpintero-Fernandez, P., et al., Intercellular communication via gap junction channels between chondrocytes and bone cells. *Biochimica et Biophysica Acta (BBA) - Biomembranes*, 2018. 1860(12): p. 2499-2505.
115. Caron, M.M., et al., Redifferentiation of dedifferentiated human articular chondrocytes: comparison of 2D and 3D cultures. *Osteoarthritis Cartilage*, 2012. 20(10): p. 1170-8.
116. Otero, M., et al., Human chondrocyte cultures as models of cartilage-specific gene regulation. *Methods Mol Biol*, 2012. 806: p. 301-36.
117. Gerber, I., et al., Stimulatory effects of creatine on metabolic activity, differentiation and mineralization of primary osteoblast-like cells in monolayer and micromass cell cultures. *Eur Cell Mater*, 2005. 10: p. 8-22.
118. Bomer, N., et al., Neo-cartilage engineered from primary chondrocytes is epigenetically similar to autologous cartilage, in contrast to using mesenchymal stem cells. *Osteoarthritis Cartilage*, 2016. 24(8): p. 1423-30.

119. van Hooijwerff, M., et al., Identification and functional characterization of imbalanced osteoarthritis associated fibronectin splice variants. *Rheumatology (Oxford)*, 2022.
120. Rodríguez Ruiz, A., et al., The role of TNFRSF11B in development of osteoarthritic cartilage. *Rheumatology (Oxford)*, 2022. 61(2): p. 856-864.
121. Geurts, J., et al., Novel Ex Vivo Human Osteochondral Explant Model of Knee and Spine Osteoarthritis Enables Assessment of Inflammatory and Drug Treatment Responses. *Int J Mol Sci*, 2018. 19(5).
122. Houtman, E., et al., Human Osteochondral Explants: Reliable Biomimetic Models to Investigate Disease Mechanisms and Develop Personalized Treatments for Osteoarthritis. *Rheumatology and Therapy*, 2021. 8(1): p. 499-515.
123. Houtman, E., et al., Inhibiting thyroid activation in aged human explants prevents mechanical induced detrimental signalling by mitigating metabolic processes. *Rheumatology*, 2022.
124. Lin, H., et al., Stem cell-based microphysiological osteochondral system to model tissue response to interleukin-1 $\beta$ . *Mol Pharm*, 2014. 11(7): p. 2203-12.
125. Lin, Z., et al., Osteochondral Tissue Chip Derived From iPSCs: Modeling OA Pathologies and Testing Drugs. *Front Bioeng Biotechnol*, 2019. 7: p. 411.
126. Hu, W., et al., Advances in crosslinking strategies of biomedical hydrogels. *Biomater Sci*, 2019. 7(3): p. 843-855.
127. Lee, H.-p., et al., Mechanical confinement regulates cartilage matrix formation by chondrocytes. *Nature Materials*, 2017. 16(12): p. 1243-1251.